ABT Stock: Abbott Shakes Off Covid Declines To Beat Expectations
Kabuhayan ABT Stock: Abbott Shakes Off Covid Tumanggi Upang Talunin ang Inaasahan Abbott Laboratories (ABT) defied its declining Covid business in the first quarter, beating expectations on the back of a rock-star medical devices segment. In response, ABT stock surged. “The medical devices division was the star of the show, growing better than our cautiously optimistic expectations,” Edward Jones analyst John Boylan said in a report to clients. “Sales were stronger than expected in heart valve, heart failure and neuromodulation products, thanks largely to product innovation.” In morning action on todays stock market, ABT stock soared 6.8%, trading near 111.20 at its highest point since early February. Abbott shares recently retook their 50-day moving average, MarketSmith.com shows. The earnings release sent shares above their 200-day line for the first time in two months. ABT Stock: Organic Growth Drove The Show During the March quarter, adjusted earnings declined 40.5% to $1.03 per share but beat expectations for 99 cents, according to FactSet. Sales fell 18.1% on a strict, as-reported basis to $9.75 billion. But the Street had projected a lower $9.67 billion. However, organic sales growth remained strong. Excluding the impact of exchange rates, exiting the pediatric nutrition business in China and declining Covid test sales, Abbotts sales grew